Report Events

[Activity Repor] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)

[Activity Repor] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)

The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery, for which AMR Alliance Japan (Secretariat: HGPI) is a cooperating member, has released recommendations on “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.”

The recommendation can be found here.
*Available Only in Japanese


■The
Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery

The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery is comprised of The Japanese Society of Chemotherapy, The Japanese Association for Infectious Disease, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society for Bacteriology, The Pharmaceutical Society of Japan, and The Japanese Society of Veterinary Science. It investigates the promotion of infectious disease therapy and drug therapy from a medical perspective.

AMR Alliance Japan

AMR Alliance Japan AMR was established in November 2018 as a multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of August 2022, its members include MSD K.K., “Kodomo to Iryo” Project, Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, NISSUI Pharmaceutical Co., Ltd., Nippon Becton Dickson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japanese Society of Hospital Pharmacists, The Pharmaceutical Society of Japan; The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.

Back to Events
PageTop